Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

被引：11

作者：

Bar, Noffar ^{[1
,2
]}

Victoria Mateos, Maria ^{[3
]}

Ribas, Paz ^{[4
]}

Hansson, Markus ^{[5
,6
]}

Paris, Laura ^{[7
]}

Hofmeister, Craig C. ^{[8
]}

Rodriguez Otero, Paula ^{[9
]}

Aranzazu Bermudez, Maria ^{[10
]}

Martin, Thomas ^{[11
]}

Santoro, Armando ^{[12
,13
]}

Yee, Andrew J. ^{[14
]}

Creignou, Maria ^{[15
]}

Encinas Rodriguez, Cristina ^{[16
]}

Cerchione, Claudio ^{[17
]}

De La Rubia, Javier ^{[18
]}

Oriol, Albert ^{[19
,20
]}

Waibel, Heidi ^{[21
]}

Besemer, Britta ^{[22
]}

Thompson, Ethan ^{[23
]}

Kiesel, Brian ^{[23
]}

Chen, Jinjie ^{[23
]}

Chung, Alexander ^{[23
]}

Boss, Isaac W. ^{[23
]}

Gaudy, Allison ^{[23
]}

Li, Shaoyi ^{[23
]}

Hsu, Kevin ^{[23
]}

Godwin, Colin ^{[23
]}

Burgess, Michael R. ^{[23
]}

San-Miguel, Jesus ^{[9
]}

Costa, Luciano ^{[24
]}

机构：

[1] Yale Univ, Dept Internal Med, Sect Hematol, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Hosp Univ Dr Peset Aleixandre, Valencia, Spain

[5] Skane Univ Hosp, Lund, Sweden

[6] Sahlgrens Univ Hosp, Gothenburg, Sweden

[7] ASST Papa Giovanni XXIII, Bergamo, Italy

[8] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA

[9] Canc Ctr Clin Univ Navarra CCUN, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[10] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[11] Univ Calif San Francisco, San Francisco, CA USA

[12] Humanitas Univ, Milan, Italy

[13] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[14] Massachusetts Gen Canc Ctr, Boston, MA USA

[15] Karolinska Univ Hosp, Phase 1 Unit, Ctr Clin Canc Studies, Stockholm, Sweden

[16] Hosp Gen Univ Gregorio Maranon, IiSGM, Madrid, Spain

[17] Ist Sci Romagnolo Studio & Cura Tumori IRS IRCCS, Meldola, FC, Italy

[18] Univ Hosp La Fe, Valencia, Spain

[19] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[20] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[21] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen, Germany

[22] Univ Hosp Tuebingen, Tubingen, Germany

[23] Bristol Myers Squibb, Princeton, NJ USA

[24] Univ Alabama Birmingham, Birmingham, AL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[31] Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Mailankody, Sham
Jakubowiak, Andrzej J.
Htut, Myo
Costa, Luciano J.
Lee, Kelvin
Ganguly, Siddhartha
Kaufman, Jonathan L.
Siegel, David Samuel DiCapua
Bensinger, William
Cota, Mariana
Doerr, Thomas
DeVries, Todd
Wong, Sandy Wai Kuan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32] A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Harrison, Simon J.
Minnema, Monique C.
Lee, Hans C.
Spencer, Andrew
Kapoor, Prashant
Madduri, Deepu
Larsen, Jeremy
Ailawadhi, Sikander
Kaufman, Jonathan L.
Raab, Marc S.
Hari, Parameswaran
Iida, Shinsuke
Vij, Ravi
Davies, Faith E.
Lesley, Robin
Upreti, Vijay V.
Yang, Zhao
Sharma, Anjali
Minella, Alex
Lentzsch, Suzanne
BLOOD, 2020, 136
[33] Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
Abdallah, Al-Ola
Cowan, Andrew J.
Leleu, Xavier
Touzeau, Cyrille
Lipe, Brea
Medvedova, Eva
Costello, Caitlin
Hillengass, Jens
Bergsagel, P. Leif
Mawad, Raya
Schade, Henning
Morillo Giles, Daniel
Oriol, Albert
Yaron, Yifah
Ng, Patrick P.
Madan, Sumit
BLOOD, 2022, 140 : 7284 - 7285
[34] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Westervelt, Peter
Roboz, Gail J.
Cortes, Jorge E.
Kantarjian, Hagop M.
Lee, Sangmin
Rettig, Michael P.
Han, Tae H.
Guenot, Jeanmarie
Feldman, Eric J.
DiPersio, John F.
BLOOD, 2018, 132
[35] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Westervelt, Peter
Cortes, Jorge E.
Altman, Jessica K.
Long, Meixiao
Oehler, Vivian G.
Gojo, Ivana
Guenot, Jeanmarie
Chun, Patrick
Roboz, Gail J.
BLOOD, 2019, 134
[36] Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.
Martin, Thomas G.
Moreau, Philippe
Usmani, Saad Zafar
Garfall, Alfred L.
Mateos, Maria-Victoria
San-Miguel, Jesus F.
Rocafiguera, Albert Oriol
Nooka, Ajay K.
Rosinol, Laura
Chari, Ajai
Karlin, Lionel
Krishnan, Amrita Y.
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez, Joaquin
Delforge, Michel
Fastenau, John
Gries, Katharine S.
van de Donk, Niels W. C. J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[37] Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation AntigenDirected Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
Martin, Thomas
Usmani, Saad Z.
Berdeja, Jesus G.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam D.
Hari, Parameswaran
Avigan, David
Deol, Abhinav
Htut, Myo
Lesokhin, Alexander
Munshi, Nikhil C.
O'Donnell, Elizabeth
Stewart, A. Keith
Schecter, Jordan M.
Goldberg, Jenna D.
Jackson, Carolyn C.
Yeh, Tzu-Min
Banerjee, Arnob
Allred, Alicia
Zudaire, Enrique
Deraedt, William
Madduri, Deepu
Olyslager, Yunsi
Zhou, Changwei
Pacaud, Lida
Lin, Yi
Jagannath, Sundar
BLOOD, 2021, 138
[38] UCARTCS1A, an Allogeneic CAR T-Cell Therapy Targeting CS1 in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Translational Results from a First-in-Human Phase I Trial (MELANI-01)
Patel, Krina
Bharathan, Mini
Esteva, Francisco J.
Siegel, David
Rossi, Adriana
Frattini, Mark G.
Smith, Julianne
Brownstein, Carrie
MOLECULAR THERAPY, 2021, 29 (04) : 59 - 60
[39] Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Madduri, Deepu
Usmani, Saad Z.
Jagannath, Sundar
Singh, Indrajeet
Zudaire, Enrique
Yeh, Tzu-Min
Allred, Alicia J.
Banerjee, Arnob
Goldberg, Jenna D.
Schecter, Jordan M.
Zhuang, Sen
Infante, Jeffrey R.
Rizvi, Syed
Fan, Xiaohu
Jakubowiak, Andrzej
Berdeja, Jesus G.
BLOOD, 2019, 134
[40] CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Usmani, Saad Z.
Martin, Thomas
Berdeja, Jesus G.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam D.
Deol, Abhinav
Htut, Myo
Lesokhin, Alexander
Munshi, Nikhil C.
O'Donnell, Elizabeth
Jackson, Carolyn C.
Yeh, Tzu-min
Banerjee, Arnob
Zudaire, Enrique
Madduri, Deepu
Zhou, Changwei
Pacaud, Lida
Lin, Yi
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S410 - S411

← 1 2 3 4 5 →